Your browser doesn't support javascript.
loading
First case of neonatal fungemia caused by Aureobasidium melanogenum.
Samaddar, Arghadip; Sharma, Anuradha.
Afiliação
  • Samaddar A; Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. Electronic address: argha2387@gmail.com.
  • Sharma A; Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
J Mycol Med ; 33(1): 101334, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36270215
ABSTRACT
Aureobasidium melanogenum is a saprophytic, dematiaceous, yeast-like fungus rarely implicated in human infections. Here, we report the first case of A. melanogenum fungemia in a 30-week-old preterm, very low birth weight neonate born to a primigravida with history of gestational diabetes, pregnancy induced hypertension and oligohydramnios. The baby developed respiratory distress, hypotension, bradycardia, coagulopathy and septic shock shortly after birth, and eventually succumbed to multiple organ dysfunction syndrome on day 9 of life. Paired blood culture showed growth of a dematiaceous yeast-like fungus which was identified as A. melanogenum by rDNA internal transcribed spacer (ITS) sequencing. Antifungal susceptibility testing of the isolate showed high minimum inhibitory concentration of fluconazole (32 µg/mL), indicating resistance. Diagnosis of A. melanogenum fungemia is difficult as it is easily confused with Candida species in Gram stained smears and similar colony morphology during the initial stages of growth. Also, the conventional diagnostic methods, such as VITEK 2 and MALDI-TOF MS are unreliable for identification of this pathogen. Accurate identification using molecular techniques is crucial for making treatment decisions as A. melanogenum shows substantial antifungal resistance. Clinicians should be aware that yeast-like cells in blood culture are not only indicative of Candida species, but also rare pathogens like A. melanogenum and should exercise caution while starting fluconazole therapy. At present, there are no established susceptibility breakpoints for Aureobasidium spp. Further studies are needed to determine the optimal treatment for such infections.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluconazol / Fungemia Tipo de estudo: Prognostic_studies Limite: Humans / Newborn Idioma: En Revista: J Mycol Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluconazol / Fungemia Tipo de estudo: Prognostic_studies Limite: Humans / Newborn Idioma: En Revista: J Mycol Med Ano de publicação: 2023 Tipo de documento: Article